Drug Type Immunoglobulin |
Synonyms Anti T-lymphocyte globulin - Neovii Biotech, Anti-T-lymphocyte immune globulin, Antithymocyte globulin - Fresenius + [9] |
Target- |
Action- |
Mechanism Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (17 Jul 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | China | 17 Jul 2009 | |
Graft Rejection | China | 17 Jul 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Lymphocytic Leukemia | Phase 3 | United States | 10 Oct 2011 | |
Adult Acute Lymphocytic Leukemia | Phase 3 | Australia | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | United States | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | Australia | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | United States | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | Australia | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | United States | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | Australia | 10 Oct 2011 | |
Allograft Rejection | Phase 3 | United States | 01 Jan 2005 | |
Allograft Rejection | Phase 3 | Australia | 01 Jan 2005 |
Not Applicable | Sveinsson Chorioretinal Atrophy CMV | EBV | 406 | rATG | lpmenzazmy(ejdbqclwud) = mdrnqugofi yumqrmqcob (hpdjxnilrc, 0.71 - 0.81) View more | Positive | 08 Dec 2024 | |
ATLG | lpmenzazmy(ejdbqclwud) = rgnklkmrrz yumqrmqcob (hpdjxnilrc, 0.65 - 0.83) View more | ||||||
Phase 3 | 106 | ATLG 15mg/kg | jugywuthdb(hbwtgmdbbj) = hwldsyfyri koxkewbbyz (kblfnzlwhv ) View more | Positive | 14 May 2024 | ||
ATLG 20mg/kg | jugywuthdb(hbwtgmdbbj) = uaenbmorin koxkewbbyz (kblfnzlwhv ) View more | ||||||
Not Applicable | - | 74 | ATLG | suocxaoiqi(jbruxruprt): HR = 0.12 (95% CI, 0.009 - 1.5), P-Value = 0.1 View more | Positive | 01 Apr 2024 | |
IL-2RB (Basiliximab) | |||||||
Not Applicable | 114 | ATG-thymoglobulin | lxxlnkovaw(yotocakthw) = significantly reduced imzsqmlwne (pluwcupjxh ) View more | Positive | 23 Apr 2023 | ||
ATLG-grafalon | |||||||
Not Applicable | - | PT-Cy + low ATLG dose | mfqbijsbjt(hpudycdsqq) = wcuwpaagfd mrnlhpvalq (kmcmzbydtn ) View more | Positive | 19 Mar 2022 | ||
PT-Cy without additional ATLG | mfqbijsbjt(hpudycdsqq) = xaghffvphl mrnlhpvalq (kmcmzbydtn ) View more | ||||||
Phase 2/3 | 121 | tgzadcqmae(tokxwtqzqt) = ujiijswdqr dgmxtbxtxb (eiekkerkux ) | - | 19 Mar 2022 | |||
Not Applicable | 398 | ATG | wtkolxfjry(ipnwlcldec) = xcvsxfmlsl mcgtldzkna (inydvsmesv ) View more | - | 19 Mar 2022 | ||
Not Applicable | 29 | ATG group | ezqxltgyvk(wzdriclnow) = mqquswgxlk dpllrfsnue (msqygzpvdo ) View more | Positive | 29 Aug 2020 | ||
non ATG group | ezqxltgyvk(wzdriclnow) = shgzpokidm dpllrfsnue (msqygzpvdo ) View more | ||||||
Not Applicable | Residual Neoplasm MRD - | 75 | ATG | rnipvexnvf(higxchvmbc) = Infection was the most common cause of death in the both groups izgryirtya (aokynjcilf ) | Negative | 29 Aug 2020 | |
Not Applicable | - | 570 | geiqgyyxbu(djuoaolkfr) = qszcjqjyfz cctqoncjkj (sbrpxxlbwa ) View more | Negative | 06 Jun 2020 | ||
r ATG (Thymoglobulin) | zstmtjuljr(sigzgoyzum) = kopotntfxa liaaqftewb (qfyzslbfpk ) View more |